{
    "id": 50746,
    "name": "mantle cell lymphoma",
    "source": "DOID",
    "definition": "A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles. [url:http\\://en.wikipedia.org/wiki/Mantle_cell_lymphoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0050746",
    "evidence": [
        {
            "id": 1353,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ONC201 induced apoptosis and decreased viability of mantle cell lymphoma (MCL) cell lines in culture and demonstrated cytotoxicity in primary MCL samples in culture (PMID: 26884599).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1687,
                "therapyName": "ONC201",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1063,
                    "pubMedId": null,
                    "title": "ONC201 Exerts p53-Independent Cytotoxicity Through TRAIL and DR5 Induction In Mantle Cell Lymphomas",
                    "url": "http://www.bloodjournal.org/content/122/21/3822.abstract"
                },
                {
                    "id": 7063,
                    "pubMedId": 26884599,
                    "title": "ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884599"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1551,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Velcade (bortezomib) induced expression of PRDM1 along with induction of apoptosis in mantle cell lymphoma cell lines (PMID: 20530581).",
            "molecularProfile": {
                "id": 2671,
                "profileName": "PRDM1 wild-type"
            },
            "therapy": {
                "id": 688,
                "therapyName": "Bortezomib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1487,
                    "pubMedId": 20530581,
                    "title": "PRDM1 is required for mantle cell lymphoma response to bortezomib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20530581"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1604,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) decreased tumor growth and angiogenesis in a xenograft model of mantle cell lymphoma positive for SOX11 and overexpressing PDGFA (PMID: 25278565, PMID: 25092176).",
            "molecularProfile": {
                "id": 26345,
                "profileName": "PDGFA over exp SOX11 pos"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1624,
                    "pubMedId": 25278565,
                    "title": "The SOX11-PDGFA axis in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25278565"
                },
                {
                    "id": 1625,
                    "pubMedId": 25092176,
                    "title": "SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25092176"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4361,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).",
            "molecularProfile": {
                "id": 17822,
                "profileName": "RB1 wild-type TP53 mut"
            },
            "therapy": {
                "id": 3497,
                "therapyName": "R547",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4503,
                    "pubMedId": 17121911,
                    "title": "In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17121911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4362,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).",
            "molecularProfile": {
                "id": 17823,
                "profileName": "RB1 wild-type TP53 wild-type"
            },
            "therapy": {
                "id": 3497,
                "therapyName": "R547",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4503,
                    "pubMedId": 17121911,
                    "title": "In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17121911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4815,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mantle cell lymphoma cells treated with BX-912 demonstrated a decrease in Pdpk1 expression and cell cycle arrest in culture (ASH Meeting, Nov 2013; Blood: 122(21)).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3657,
                "therapyName": "BX-912",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4746,
                    "pubMedId": null,
                    "title": "High Efficiency Of the PDPK1-Inhibitor, BX912, In MCL",
                    "url": "http://www.bloodjournal.org/content/122/21/3077?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4905,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Abexinostat treatment resulted in an overall response rate of 27.3% (3/11) mantle cell lymphoma patients with a median progression-free survival of 3.9 months (PMID: 26482040).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1081,
                "therapyName": "Abexinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4787,
                    "pubMedId": 26482040,
                    "title": "A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26482040"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5130,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Aliqopa (copanlisib) treatment resulted in complete response in 17% (1/6) and partial response in 67% (4/6) of patients with mantle cell lymphoma (PMID: 24852792).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 995,
                "therapyName": "Copanlisib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4879,
                    "pubMedId": 24852792,
                    "title": "Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24852792"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5247,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Piceatannol inhibited growth of a mantle cell lymphoma cell line with SYK amplification and overexpression in culture (PMID: 16409295).",
            "molecularProfile": {
                "id": 17588,
                "profileName": "SYK amp"
            },
            "therapy": {
                "id": 3783,
                "therapyName": "Piceatannol",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4475,
                    "pubMedId": 16409295,
                    "title": "Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16409295"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5998,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ST7612AA1 inhibited proliferation of mantle cell lymphoma cell lines in culture (PMID: 25671299).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3989,
                "therapyName": "ST7612AA1",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5200,
                    "pubMedId": 25671299,
                    "title": "Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25671299"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7681,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mantle cell lymphoma cell line with ATM inactivation demonstrated sensitivity to Lynparza (olaparib) in culture and in xenograft models (PMID: 20739657).",
            "molecularProfile": {
                "id": 522,
                "profileName": "ATM inact mut"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 137,
                    "pubMedId": 20739657,
                    "title": "The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20739657"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7693,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) sensitized a mantle cell lymphoma cell line harboring an ATM inactivating mutation to Treanda (bendamustine) in cell culture, resulting in growth inhibition (PMID: 20739657).",
            "molecularProfile": {
                "id": 522,
                "profileName": "ATM inact mut"
            },
            "therapy": {
                "id": 4548,
                "therapyName": "Bendamustine + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 137,
                    "pubMedId": 20739657,
                    "title": "The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20739657"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7696,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Lynparza (olaparib) and valproic acid worked synergistically to inhibit growth of a mantle cell lymphoma cell line harboring an ATM inactivating mutation in culture (PMID: 20739657).",
            "molecularProfile": {
                "id": 522,
                "profileName": "ATM inact mut"
            },
            "therapy": {
                "id": 4549,
                "therapyName": "Olaparib + Valproic acid",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 137,
                    "pubMedId": 20739657,
                    "title": "The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20739657"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7701,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) sensitized a mantle cell lymphoma cell line harboring an ATM inactivating mutation to Fludara (fludarabine) in cell culture, resulting in decreased cell survival (PMID: 20739657).",
            "molecularProfile": {
                "id": 522,
                "profileName": "ATM inact mut"
            },
            "therapy": {
                "id": 4550,
                "therapyName": "Fludarabine + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 137,
                    "pubMedId": 20739657,
                    "title": "The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20739657"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8364,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zydelig (idelalisib) inhibited PI3K/Akt pathway activation, and resulted in growth inhibition in both patient-derived and established mantle cell lymphoma cell lines in culture (PMID: 27342398).",
            "molecularProfile": {
                "id": 20237,
                "profileName": "PIK3CD positive"
            },
            "therapy": {
                "id": 1023,
                "therapyName": "Idelalisib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6635,
                    "pubMedId": 27342398,
                    "title": "Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27342398"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8784,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ML364 induced Ccnd1 degradation and inhibited survival of mantle cell lymphoma cells in a dose-dependent manner in culture (PMID: 27681596).",
            "molecularProfile": {
                "id": 2445,
                "profileName": "CCND1 positive"
            },
            "therapy": {
                "id": 4811,
                "therapyName": "ML364",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6749,
                    "pubMedId": 27681596,
                    "title": "Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27681596"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9024,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, treatment with ONO-4059 was well tolerated and resulted in responses in 92% (11/12) of patients with mantle cell lymphoma (PMID: 26542378).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2691,
                "therapyName": "ONO-4059",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6866,
                    "pubMedId": 26542378,
                    "title": "A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26542378"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9293,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of ONC201and Venclexta (venetoclax) demonstrated synergy in a mantle cell lymphoma cell line in culture, resulting in increased induction of apoptosis (PMID: 26884599).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4964,
                "therapyName": "ONC201 + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7063,
                    "pubMedId": 26884599,
                    "title": "ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884599"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9295,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of ONC201 and Imbruvica (ibrutinib) induced apoptosis in primary mantle cell lymphoma samples in culture, including Imbruvica (ibrutinib)-resistant samples, with greater efficacy than either agent alone (PMID: 26884599).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4965,
                "therapyName": "Ibrutinib + ONC201",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7063,
                    "pubMedId": 26884599,
                    "title": "ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26884599"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9419,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Brukinsa (zanubrutinib) inhibited BTK signaling and proliferation of mantle cell lymphoma cell lines in culture, and demonstrated antitumor activity in a mantle cell lymphoma cell line xenograft model (ibrutinib) (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2597).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2544,
                "therapyName": "Zanubrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7182,
                    "pubMedId": null,
                    "title": "BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/2597"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19235,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (BGB-3111-206) that supported FDA approval, Brukinsa (zanubrutinib) treatment resulted in an overall response rate of 83.5% (71/85, 50 complete response, 21 partial response) of patients with relapsed or refractory mantle cell lymphoma who received 1 to 4 prior treatments (Blood (2018) 132 (Supplement 1): 148; NCT03206970).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2544,
                "therapyName": "Zanubrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16803,
                    "pubMedId": null,
                    "title": "Brukinsa (zanubrutinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213217"
                },
                {
                    "id": 16805,
                    "pubMedId": null,
                    "title": "Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial",
                    "url": "https://ashpublications.org/blood/article-abstract/132/Supplement%201/148/273151/Safety-and-Activity-of-the-Investigational-Bruton?redirectedFrom=fulltext"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9874,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mantle cell lymphoma cell lines demonstrated greater cell growth inhibition when treated with a combination of GS-5829 and Venclexta (venetoclax) compared to either agent alone in culture (Blood 2016 128:5104).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5277,
                "therapyName": "GS-5829 + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7727,
                    "pubMedId": null,
                    "title": "Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines",
                    "url": "http://www.bloodjournal.org/content/128/22/5104?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9998,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Copiktra (duvelisib) inhibited proliferation, and resulted in an increase in activation-induced cytidine deaminase (AID) expression and genomic instability in a mantle cell lymphoma cell line in culture (PMID: 28199309).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1024,
                "therapyName": "Duvelisib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7890,
                    "pubMedId": 28199309,
                    "title": "Phosphatidylinositol 3-kinase \u03b4 blockade increases genomic instability in B cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28199309"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11140,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Rituximab and Bendamustine combination therapy resulted in improved 5-year progression free survival rate (66.5% vs 55.8%), but no difference in overall survival rate (81.7% vs 85%) compared to R-CHOP/R-CVP regimen in patients with indolent non-Hodgkin lymphoma or mantle cell lymphoma (J Clin Oncol 35, 2017 (suppl; abstr 7500)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2323,
                "therapyName": "Bendamustine + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9106,
                    "pubMedId": null,
                    "title": "First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study.",
                    "url": "http://meetinglibrary.asco.org/record/147107/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11577,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mantle cell lymphoma cell line expressing CARD11 G123S was resistant to treatment with Revlimid (lenalidomide) in culture (PMID: 27224912).",
            "molecularProfile": {
                "id": 28149,
                "profileName": "CARD11 G123S"
            },
            "therapy": {
                "id": 1164,
                "therapyName": "Lenalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9619,
                    "pubMedId": 27224912,
                    "title": "Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27224912"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11582,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mantle cell lymphoma cell line expressing CARD11 G123S was resistant to treatment with Imbruvica (ibrutinib) in culture (PMID: 27224912).",
            "molecularProfile": {
                "id": 28149,
                "profileName": "CARD11 G123S"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9619,
                    "pubMedId": 27224912,
                    "title": "Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27224912"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11583,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mantle cell lymphoma cell line expressing CARD11 D230N was resistant to treatment with Imbruvica (ibrutinib) in culture (PMID: 27224912).",
            "molecularProfile": {
                "id": 28153,
                "profileName": "CARD11 D230N"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9619,
                    "pubMedId": 27224912,
                    "title": "Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27224912"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11584,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mantle cell lymphoma cell line expressing CARD11 D230N was resistant to treatment with Revlimid (lenalidomide) in culture (PMID: 27224912).",
            "molecularProfile": {
                "id": 28153,
                "profileName": "CARD11 D230N"
            },
            "therapy": {
                "id": 1164,
                "therapyName": "Lenalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9619,
                    "pubMedId": 27224912,
                    "title": "Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27224912"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11585,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mantle cell lymphoma cell line expressing CARD11 D357E was resistant to treatment with Revlimid (lenalidomide) in culture (PMID: 27224912).",
            "molecularProfile": {
                "id": 28159,
                "profileName": "CARD11 D357E"
            },
            "therapy": {
                "id": 1164,
                "therapyName": "Lenalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9619,
                    "pubMedId": 27224912,
                    "title": "Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27224912"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11586,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mantle cell lymphoma cell line expressing CARD11 D357E was resistant to treatment with Imbruvica (ibrutinib) in culture (PMID: 27224912).",
            "molecularProfile": {
                "id": 28159,
                "profileName": "CARD11 D357E"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9619,
                    "pubMedId": 27224912,
                    "title": "Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27224912"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11587,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mantle cell lymphoma cell line expressing CARD11 Y361C was resistant to treatment with Imbruvica (ibrutinib) in culture (PMID: 27224912).",
            "molecularProfile": {
                "id": 28161,
                "profileName": "CARD11 Y361C"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9619,
                    "pubMedId": 27224912,
                    "title": "Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27224912"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11588,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mantle cell lymphoma cell line expressing CARD11 Y361C was resistant to treatment with Revlimid (lenalidomide) in culture (PMID: 27224912).",
            "molecularProfile": {
                "id": 28161,
                "profileName": "CARD11 Y361C"
            },
            "therapy": {
                "id": 1164,
                "therapyName": "Lenalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9619,
                    "pubMedId": 27224912,
                    "title": "Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27224912"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12117,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Umbralisib (TGR-1202) treatment resulted in partial response in 17% (1/6) and stable disease in 67% (4/6) of patients with mantle cell lymphoma (PMID: 29475723; NCT01767766).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2022,
                "therapyName": "Umbralisib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11343,
                    "pubMedId": 29475723,
                    "title": "Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29475723"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12249,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Imbruvica (ibrutinib) treatment resulted in a response rate of 68% (75/111, complete response 21%, partial response 47%), with an estimated median progression-free survival of 13.9 months in patients with relapsed or refractory mantle-cell lymphoma (PMID: 23782157, NCT01236391).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10209,
                    "pubMedId": 23782157,
                    "title": "Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23782157"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12250,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, BTK C418S was identified as an acquired mutation that confers resistance to Imbruvica (ibrutinib) in two patients with mantle cell lymphoma who relapsed after a durable response (PMID: 25082755).",
            "molecularProfile": {
                "id": 2309,
                "profileName": "BTK C481S"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10210,
                    "pubMedId": 25082755,
                    "title": "Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25082755"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13554,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical study, mantle cell lymphoma patient derived cell lines demonstrated improved survival in culture when treated with CC214-1 (PMID: 25839159).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3853,
                "therapyName": "CC214-1",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11174,
                    "pubMedId": 25839159,
                    "title": "Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25839159"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14316,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Buparlisib (BKM120) and Imbruvica (ibrutinib) combination treatment resulted in a best overall response rate of 88% (15/17, 11 complete response, 4 partial response) in patients with relapsed/refractory mantle cell lymphoma (J Clin Oncol 36, 2018 (suppl; abstr 7520); NCT02756247).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3630,
                "therapyName": "Buparlisib + Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11582,
                    "pubMedId": null,
                    "title": "Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.",
                    "url": "http://abstracts.asco.org/214/AbstView_214_229221.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14317,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Imbruvica (ibrutinib) and Ibrance (palbociclib) combination treatment resulted in an overall response rate of 67%, a complete response rate of 37%, and a two year progression-free survival in 59.4% of patients with previously treated mantle cell lymphoma, with a median follow up of 25.6 months (PMID: 30692121; NCT02159755).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1729,
                "therapyName": "Ibrutinib + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11584,
                    "pubMedId": null,
                    "title": "A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma",
                    "url": "http://www.bloodjournal.org/content/128/22/150?sso-checked=true"
                },
                {
                    "id": 14556,
                    "pubMedId": 30692121,
                    "title": "A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30692121"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14348,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, IRF4 was down-regulated in mantle cell lymphoma cells isolated from patients who responded to Ibrance (palbociclib) therapy compared to cells from nonresponders, and loss of IRF4 induced interferon response and apoptosis in cultured cells, suggesting that IRF4 may be a biomarker predicting sensitivity to Cdk4 inhibition (Cancer Res 2018;78(13 Suppl):Abstract nr 1523).",
            "molecularProfile": {
                "id": 29982,
                "profileName": "IRF4 loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11604,
                    "pubMedId": null,
                    "title": "Repression of IRF4 and CYTIP unleashes anti-tumor interferon response in CDK4 inhibitor therapy in mantle cell lymphoma",
                    "url": "http://cancerres.aacrjournals.org/content/78/13_Supplement/1523"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14349,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Venclexta (venetoclax) treatment resulted in an overall response rate of 60% (12/20, 4 complete response), with a median progression-free survival of 2.6 months, and a median overall survival of 4.3 months in patients with relapsed/refractory mantle cell lymphoma who failed BTK inhibitor therapy (EHA23, June 2018, abstract S855).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11605,
                    "pubMedId": null,
                    "title": "EFFICACY OF VENETOCLAX MONOTHERAPY IN PATIENTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA POST BTK INHIBITION THERAPY.",
                    "url": "https://learningcenter.ehaweb.org/eha/2018/stockholm/214548/toby.eyre.efficacy.of.venetoclax.monotherapy.in.patients.with.relapsed.html?f=media=3"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15071,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, STRO-001 potently inhibited growth of mantle cell lymphoma cell lines in culture (Blood 2016 128 (22):464).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7413,
                "therapyName": "STRO-001",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12622,
                    "pubMedId": null,
                    "title": "Targeting CD74 with Novel Antibody Drug Conjugates (ADCs) for the Treatment of B-Cell Non-Hodgkin's Lymphoma (NHL)",
                    "url": "http://www.bloodjournal.org/content/128/22/464?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15913,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mantle cell lymphoma cells expressing CCND1 E36K demonstrated resistance to treatment with Imbruvica (ibrutinib) in culture (PMID: 27713153).",
            "molecularProfile": {
                "id": 31314,
                "profileName": "CCND1 E36K"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14006,
                    "pubMedId": 27713153,
                    "title": "CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27713153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15914,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mantle cell lymphoma cells expressing CCND1 Y44D demonstrated resistance to treatment with Imbruvica (ibrutinib) in culture (PMID: 27713153).",
            "molecularProfile": {
                "id": 31315,
                "profileName": "CCND1 Y44D"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14006,
                    "pubMedId": 27713153,
                    "title": "CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27713153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15915,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a mantle cell lymphoma patient-derived cell line harboring CCND1 C47S demonstrated resistance to treatment with Imbruvica (ibrutinib) in culture, however, a different patient-derived cell line with C47S was sensitive to Imbruvica (ibrutinib) treatment in culture, demonstrating reduced cell viability (PMID: 27713153).",
            "molecularProfile": {
                "id": 31316,
                "profileName": "CCND1 C47S"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 14006,
                    "pubMedId": 27713153,
                    "title": "CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27713153"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15916,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mantle cell lymphoma cells expressing CCND1 E36K demonstrated resistance to treatment with Zydelig (idelalisib) in culture (PMID: 27713153).",
            "molecularProfile": {
                "id": 31314,
                "profileName": "CCND1 E36K"
            },
            "therapy": {
                "id": 1023,
                "therapyName": "Idelalisib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14006,
                    "pubMedId": 27713153,
                    "title": "CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27713153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15917,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mantle cell lymphoma cells expressing CCND1 Y44D demonstrated resistance to treatment with Zydelig (idelalisib) in culture (PMID: 27713153).",
            "molecularProfile": {
                "id": 31315,
                "profileName": "CCND1 Y44D"
            },
            "therapy": {
                "id": 1023,
                "therapyName": "Idelalisib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14006,
                    "pubMedId": 27713153,
                    "title": "CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27713153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15918,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mantle cell lymphoma cells expressing CCND1 C47S demonstrated resistance to treatment with Zydelig (idelalisib) in culture (PMID: 27713153).",
            "molecularProfile": {
                "id": 31316,
                "profileName": "CCND1 C47S"
            },
            "therapy": {
                "id": 1023,
                "therapyName": "Idelalisib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14006,
                    "pubMedId": 27713153,
                    "title": "CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27713153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15919,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mantle cell lymphoma cells expressing CCND1 C47S demonstrated resistance to treatment with Torkinib (PP242) in culture (PMID: 27713153).",
            "molecularProfile": {
                "id": 31316,
                "profileName": "CCND1 C47S"
            },
            "therapy": {
                "id": 2240,
                "therapyName": "Torkinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14006,
                    "pubMedId": 27713153,
                    "title": "CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27713153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15920,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mantle cell lymphoma cells expressing CCND1 E36K demonstrated resistance to treatment with Torkinib (PP242) in culture (PMID: 27713153).",
            "molecularProfile": {
                "id": 31314,
                "profileName": "CCND1 E36K"
            },
            "therapy": {
                "id": 2240,
                "therapyName": "Torkinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14006,
                    "pubMedId": 27713153,
                    "title": "CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27713153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15921,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mantle cell lymphoma cells expressing CCND1 Y44D demonstrated resistance to treatment with Torkinib (PP242) in culture (PMID: 27713153).",
            "molecularProfile": {
                "id": 31315,
                "profileName": "CCND1 Y44D"
            },
            "therapy": {
                "id": 2240,
                "therapyName": "Torkinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14006,
                    "pubMedId": 27713153,
                    "title": "CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27713153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15960,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the MS4A1 antibody, MT-3724, resulted in cell growth inhibition in 6/8 mantle cell lymphoma cell lines resistant to Imbruvica (ibrutinib) and led to decreased tumor volume and increased overall survival compared to control in a mantle cell lymphoma patient-derived xenograft (PDX) model, also resistant to Imbruvica (ibrutinib) (PMID: 29559616).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 7831,
                "therapyName": "MT-3724",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14076,
                    "pubMedId": 29559616,
                    "title": "The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29559616"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15963,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Imbruvica (ibrutinib) and MS4A1 antibody, MT-3724, resulted in a synergistic effect, inducing apoptosis in Imbruvica (ibrutinib)-resistant mantle cell lymphoma cell lines in culture (PMID: 29559616).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 7832,
                "therapyName": "Ibrutinib + MT-3724",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14076,
                    "pubMedId": 29559616,
                    "title": "The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29559616"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15964,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Venetoclax (ABT-199) and the MS4A1 antibody, MT-3724, resulted in a synergistic effect, demonstrating growth inhibition and induced apoptosis in mantle cell lymphoma cell lines in culture (PMID: 29559616).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 7833,
                "therapyName": "MT-3724 + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14076,
                    "pubMedId": 29559616,
                    "title": "The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29559616"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16494,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-nodal leukemic mantle cell lymphoma with TP53 loss, as well as a CCND1 translocation, had no response to combined Rituxan (rituximab) and Treanda (bendamustine) therapy, and had a doubling of white blood cells during two cycles of treatment (PMID: 30559058).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 2323,
                "therapyName": "Bendamustine + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14568,
                    "pubMedId": 30559058,
                    "title": "Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30559058"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16497,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-nodal leukemic mantle cell lymphoma with TP53 loss, as well as a CCND1 translocation, had a rapid response to combined Rituxan (rituximab) and Imbruvica (ibrutinib) therapy, achieved a complete remission (CR) within 6 months, underwent autologous stem-cell transplantation, and remained in CR 18 months thereafter (PMID: 30559058).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 3280,
                "therapyName": "Ibrutinib + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14568,
                    "pubMedId": 30559058,
                    "title": "Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30559058"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16499,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-nodal leukemic mantle cell lymphoma harboring TP53 G244S, as well as KMT2A V2593A and BCOR S830Cfs*6, achieved complete remission (CR) with no evident minimum residual disease after 5 months of combined Rituxan (rituximab) and Imbruvica (ibrutinib) therapy, and following subsequent autologous stem-cell transplantation remained in CR beyond 18 months (PMID: 30559058).",
            "molecularProfile": {
                "id": 31642,
                "profileName": "TP53 G244S"
            },
            "therapy": {
                "id": 3280,
                "therapyName": "Ibrutinib + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14568,
                    "pubMedId": 30559058,
                    "title": "Aggressive Leukemic Non-Nodal Mantle Cell Lymphoma With P53 Gene Rearrangement/Mutation is Highly Responsive to Rituximab/Ibrutinib Combination Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30559058"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16522,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Parsaclisib (INCB050465) treatment demonstrated tolerability and preliminary activity in patients with refractory B-cell malignancies, and resulted in an overall response rate of 67 (6/9), complete response/complete metabolic response rate of 44% (4/9), and median duration of response was not reached in patients with mantle cell lymphoma (PMID: 30803990; NCT02018861).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3088,
                "therapyName": "Parsaclisib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14606,
                    "pubMedId": 30803990,
                    "title": "Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30803990"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16706,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AGS67E inhibited growth of 2 of 3 CD37-positive mantle cell lymphoma cell lines in culture, and inhibited tumor growth in xenograft models (PMID: 25934707).",
            "molecularProfile": {
                "id": 30535,
                "profileName": "CD37 positive"
            },
            "therapy": {
                "id": 8154,
                "therapyName": "AGS67E",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14736,
                    "pubMedId": 25934707,
                    "title": "AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25934707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16814,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (AIM), distinct molecular profiles were identified in mantle cell lymphoma patients responded to Imbruvica (ibrutinib) and Venclexta (venetoclax) combination therapy compared to those did not respond, with all patients harboring mutations in NSD2 (n=4), UBR5 (n=3), KMT2D (n=3), and 12 of 13 patients harboring mutations in ATM responded to the therapy, while SMARCA4 (n=4), CCND1 (n=2), and NOTCH1 (n=3) alterations were exclusively observed in nonresponders (PMID: 30455436; NCT02471391).",
            "molecularProfile": {
                "id": 31970,
                "profileName": "NSD2 mutant"
            },
            "therapy": {
                "id": 3392,
                "therapyName": "Ibrutinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14918,
                    "pubMedId": 30455436,
                    "title": "Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30455436"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16815,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (AIM), distinct molecular profiles were identified in mantle cell lymphoma patients responded to Imbruvica (ibrutinib) and Venclexta (venetoclax) combination therapy compared to those did not respond, with all patients harboring mutations in NSD2 (n=4), UBR5 (n=3), KMT2D (n=3), and 12 of 13 patients harboring mutations in ATM responded to the therapy, while SMARCA4 (n=4), CCND1 (n=2), and NOTCH1 (n=3) alterations were exclusively observed in nonresponders (PMID: 30455436; NCT02471391).",
            "molecularProfile": {
                "id": 31974,
                "profileName": "UBR5 mutant"
            },
            "therapy": {
                "id": 3392,
                "therapyName": "Ibrutinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14918,
                    "pubMedId": 30455436,
                    "title": "Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30455436"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16816,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (AIM), distinct molecular profiles were identified in mantle cell lymphoma patients responded to Imbruvica (ibrutinib) and Venclexta (venetoclax) combination therapy compared to those did not respond, with all patients harboring mutations in NSD2 (n=4), UBR5 (n=3), KMT2D (n=3), and 12 of 13 patients harboring mutations in ATM responded to the therapy, while SMARCA4 (n=4), CCND1 (n=2), and NOTCH1 (n=3) alterations were exclusively observed in nonresponders (PMID: 30455436; NCT02471391).",
            "molecularProfile": {
                "id": 28032,
                "profileName": "KMT2D mutant"
            },
            "therapy": {
                "id": 3392,
                "therapyName": "Ibrutinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14918,
                    "pubMedId": 30455436,
                    "title": "Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30455436"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16817,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (AIM), distinct molecular profiles were identified in mantle cell lymphoma patients responded to Imbruvica (ibrutinib) and Venclexta (venetoclax) combination therapy compared to those did not respond, with all patients harboring mutations in NSD2 (n=4), UBR5 (n=3), KMT2D (n=3), and 12 of 13 patients harboring mutations in ATM responded to the therapy, while SMARCA4 (n=4), CCND1 (n=2), and NOTCH1 (n=3) alterations were exclusively observed in nonresponders (PMID: 30455436; NCT02471391).",
            "molecularProfile": {
                "id": 3274,
                "profileName": "ATM mutant"
            },
            "therapy": {
                "id": 3392,
                "therapyName": "Ibrutinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14918,
                    "pubMedId": 30455436,
                    "title": "Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30455436"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16818,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (AIM), distinct molecular profiles were identified in mantle cell lymphoma patients responded to Imbruvica (ibrutinib) and Venclexta (venetoclax) combination therapy compared to those did not respond, with all patients harboring mutations in NSD2 (n=4), UBR5 (n=3), KMT2D (n=3), and 12 of 13 patients harboring mutations in ATM responded to the therapy, while SMARCA4 (n=4), CCND1 (n=2), and NOTCH1 (n=3) alterations were exclusively observed in nonresponders (PMID: 30455436; NCT02471391).",
            "molecularProfile": {
                "id": 22426,
                "profileName": "SMARCA4 mutant"
            },
            "therapy": {
                "id": 3392,
                "therapyName": "Ibrutinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14918,
                    "pubMedId": 30455436,
                    "title": "Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30455436"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16819,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (AIM), distinct molecular profiles were identified in mantle cell lymphoma patients responded to Imbruvica (ibrutinib) and Venclexta (venetoclax) combination therapy compared to those did not respond, with all patients harboring mutations in NSD2 (n=4), UBR5 (n=3), KMT2D (n=3), and 12 of 13 patients harboring mutations in ATM responded to the therapy, while SMARCA4 (n=4), CCND1 (n=2), and NOTCH1 (n=3) alterations were exclusively observed in nonresponders (PMID: 30455436; NCT02471391).",
            "molecularProfile": {
                "id": 27744,
                "profileName": "CCND1 mutant"
            },
            "therapy": {
                "id": 3392,
                "therapyName": "Ibrutinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14918,
                    "pubMedId": 30455436,
                    "title": "Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30455436"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16820,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (AIM), distinct molecular profiles were identified in mantle cell lymphoma patients responded to Imbruvica (ibrutinib) and Venclexta (venetoclax) combination therapy compared to those did not respond, with all patients harboring mutations in NSD2 (n=4), UBR5 (n=3), KMT2D (n=3), and 12 of 13 patients harboring mutations in ATM responded to the therapy, while SMARCA4 (n=4), CCND1 (n=2), and NOTCH1 (n=3) alterations were exclusively observed in nonresponders (PMID: 30455436; NCT02471391).",
            "molecularProfile": {
                "id": 14278,
                "profileName": "NOTCH1 mutant"
            },
            "therapy": {
                "id": 3392,
                "therapyName": "Ibrutinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14918,
                    "pubMedId": 30455436,
                    "title": "Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30455436"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17124,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (EMERGE) that supported FDA approval, Revlimid (lenalidomide) treatment resulted in an objective response rate of 28% (37/134) with rapid time to response (2.2 months), a median duration of response of 16.6 months, a median progression-free survival of 4.0 months, and a median overall survival of 19.0 months in patients with mantle cell lymphoma who relapsed or progressed after or were refractory to Velcade (bortezomib) (PMID: 24002500; NCT00737529).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1164,
                "therapyName": "Lenalidomide",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15201,
                    "pubMedId": 24002500,
                    "title": "Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24002500"
                },
                {
                    "id": 15666,
                    "pubMedId": null,
                    "title": "Revlimid (lenalidomide) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021880"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17539,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PINNACLE) that supported FDA approval, Velcade (bortezomib) monotherapy resulted in an overall response rate of 31% (48/155, 12 complete response, 36 partial response) in patients with relapsed or refractory mantle cell lymphoma, with a median overall survival not reached after a median follow-up of 13.4 months (PMID: 17001068; NCT00063713).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 688,
                "therapyName": "Bortezomib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15605,
                    "pubMedId": null,
                    "title": "Velcade (Bortezomib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021602"
                },
                {
                    "id": 15628,
                    "pubMedId": 17001068,
                    "title": "Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17001068"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17538,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, substituting Velcade (bortezomib) for vincristine in R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) resulted in improved progression-free survival (24.7 vs 14.4 months, HR=0.63, p<0.001) compared to R-CHOP in patients with newly diagnosed mantle cell lymphoma (PMID: 25738670; NCT00722137).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 688,
                "therapyName": "Bortezomib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15605,
                    "pubMedId": null,
                    "title": "Velcade (Bortezomib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021602"
                },
                {
                    "id": 15626,
                    "pubMedId": 25738670,
                    "title": "Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25738670"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17583,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAX G179E was identified as an acquired mutation in a mantle cell lymphoma (MCL) cell line with resistance to Venclexta (venetoclax) in culture and in xenograft models, and expression of BAX G179E was unable to restore sensitivity to Venclexta (venetoclax) in Venclexta (venetoclax)-resistant MCL cells in culture (PMID: 24786774).",
            "molecularProfile": {
                "id": 32688,
                "profileName": "BAX G179E"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15676,
                    "pubMedId": 24786774,
                    "title": "Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24786774"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17698,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mantle cell lymphoma cells expressing CCND1 T286A demonstrated resistance to treatment with Imbruvica (ibrutinib) in culture (PMID: 27713153).",
            "molecularProfile": {
                "id": 32091,
                "profileName": "CCND1 T286A"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14006,
                    "pubMedId": 27713153,
                    "title": "CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27713153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19271,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (ACE-LY-004) that supported FDA approval, Calquence (acalabrutinib) treatment resulted in an overall response rate of 81% (100/124, 49 complete response) in patients with relapsed or refractory mantle cell lymphoma (PMID: 29241979; NCT02213926).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1605,
                "therapyName": "Acalabrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16852,
                    "pubMedId": null,
                    "title": "Calquence (acalabrutinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210259"
                },
                {
                    "id": 16854,
                    "pubMedId": 29241979,
                    "title": "Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29241979"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20202,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "SOX11 mutations aid the diagnosis of mantle cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 34921,
                "profileName": "SOX11 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20203,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "IGH mutations aid the diagnosis of mantle cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 28306,
                "profileName": "IGH mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20613,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, MOR208 treatment was well-tolerated and resulted in stable disease as the best response in 50% (6/12) of patients with mantle cell lymphoma (PMID: 29444231; NCT01685008).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5783,
                "therapyName": "MOR208",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17962,
                    "pubMedId": 29444231,
                    "title": "Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29444231"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20658,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (ZUMA-2) trial, conditioning chemotherapy including Cytoxan (cyclophosphamide) and Flurdara (fludarabine) followed by a single infusion of KTE-X19 resulted in an objective response rate of 86% (24/28, 16 complete response, 8 partial response) in patients with relapsed/refractory mantle cell lymphoma (Blood (2019) 134 (Supplement_1): 754).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9415,
                "therapyName": "Cyclophosphamide + Fludarabine + KTE-X19",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17977,
                    "pubMedId": null,
                    "title": "KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study.",
                    "url": "https://doi.org/10.1182/blood-2019-126064"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00114738",
            "title": "EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3395,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00602693",
            "title": "T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 917,
                    "therapyName": "Sirolimus",
                    "synonyms": null
                },
                {
                    "id": 2311,
                    "therapyName": "Allopurinol + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00671112",
            "title": "Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2234,
                    "therapyName": "Bortezomib + Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00878254",
            "title": "Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7680,
                    "therapyName": "Cyclophosphamide + Cytarabine + Doxorubicin + Etoposide + Filgrastim + Ifosfamide + Leucovorin + Mesna + Methotrexate + Rituximab + Vincristine",
                    "synonyms": "R-MACLO/IVAM"
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01111188",
            "title": "Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1730,
                    "therapyName": "Bortezomib + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01180049",
            "title": "Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma",
            "phase": "FDA approved",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01251575",
            "title": "Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 2270,
                    "therapyName": "Cyclosporine + Mycophenolate mofetil + Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01267812",
            "title": "Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1649,
                    "therapyName": "Bortezomib + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01415752",
            "title": "Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 1231,
                    "therapyName": "Bendamustine",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01439750",
            "title": "Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3394,
                    "therapyName": "Bortezomib + Cladribine + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01686165",
            "title": "Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1078,
                    "therapyName": "Belinostat",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01695941",
            "title": "Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3581,
                    "therapyName": "Alisertib + Bortezomib + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01719250",
            "title": "Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 680,
                    "therapyName": "Buparlisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01796171",
            "title": "A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7920,
                    "therapyName": "Lilotomab",
                    "synonyms": null
                },
                {
                    "id": 7393,
                    "therapyName": "Betalutin",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01799889",
            "title": "A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2522,
                    "therapyName": "Entospletinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01804686",
            "title": "A Long-term Extension Study of PCI-32765 (Ibrutinib)",
            "phase": "Phase III",
            "recruitment": "Enrolling by invitation",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01811368",
            "title": "Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9105,
                    "therapyName": "anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 2272,
                    "therapyName": "Cyclosporine + Mycophenolate mofetil",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01880567",
            "title": "Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3280,
                    "therapyName": "Ibrutinib + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01897012",
            "title": "Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1075,
                    "therapyName": "Romidepsin",
                    "synonyms": null
                },
                {
                    "id": 626,
                    "therapyName": "Alisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01905813",
            "title": "Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2420,
                    "therapyName": "INCB040093 + Itacitinib",
                    "synonyms": null
                },
                {
                    "id": 2021,
                    "therapyName": "INCB040093",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01955499",
            "title": "Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3580,
                    "therapyName": "Ibrutinib + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01994382",
            "title": "Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2531,
                    "therapyName": "Cerdulatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02000934",
            "title": "A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3146,
                    "therapyName": "TAK-659",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02018861",
            "title": "A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2406,
                    "therapyName": "Itacitinib",
                    "synonyms": null
                },
                {
                    "id": 3097,
                    "therapyName": "Itacitinib + Parsaclisib",
                    "synonyms": null
                },
                {
                    "id": 1231,
                    "therapyName": "Bendamustine",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 2352,
                    "therapyName": "Carboplatin + Etoposide + Ifosfamide",
                    "synonyms": null
                },
                {
                    "id": 3088,
                    "therapyName": "Parsaclisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02049541",
            "title": "Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2502,
                    "therapyName": "Buparlisib + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02106091",
            "title": "Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7390,
                    "therapyName": "AFM11",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02159755",
            "title": "Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1729,
                    "therapyName": "Ibrutinib + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02203903",
            "title": "Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9602,
                    "therapyName": "MultiTAA-specific T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02208037",
            "title": "Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT02213926",
            "title": "An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1605,
                    "therapyName": "Acalabrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02242097",
            "title": "Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02268851",
            "title": "A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2044,
                    "therapyName": "Ibrutinib + Umbralisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02269085",
            "title": "A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3282,
                    "therapyName": "Carfilzomib + Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02285244",
            "title": "Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 621,
                    "therapyName": "AEB071",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02303392",
            "title": "Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3579,
                    "therapyName": "Ibrutinib + Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02328014",
            "title": "ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3265,
                    "therapyName": "ACP-319",
                    "synonyms": null
                },
                {
                    "id": 1605,
                    "therapyName": "Acalabrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02339922",
            "title": "Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6730,
                    "therapyName": "Ixazomib + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02381080",
            "title": "Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3793,
                    "therapyName": "Erythromycin + Ibrutinib + Voriconazole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02419560",
            "title": "Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3392,
                    "therapyName": "Ibrutinib + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02420795",
            "title": "Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1687,
                    "therapyName": "ONC201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02427620",
            "title": "A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2353,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 3195,
                    "therapyName": "Cytarabine + Methotrexate",
                    "synonyms": null
                },
                {
                    "id": 1642,
                    "therapyName": "Leucovorin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02440685",
            "title": "A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7391,
                    "therapyName": "ASN002",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02446236",
            "title": "Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1610,
                    "therapyName": "Ibrutinib + Lenalidomide + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02454270",
            "title": "A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4166,
                    "therapyName": "JNJ-64052781",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02455297",
            "title": "Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 995,
                    "therapyName": "Copanlisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02489123",
            "title": "Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1262,
                    "therapyName": "Enzalutamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02564744",
            "title": "Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6931,
                    "therapyName": "IMGN529 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02572453",
            "title": "AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 645,
                    "therapyName": "Onalespib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02601313",
            "title": "A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5098,
                    "therapyName": "Cyclophosphamide + Fludarabine + KTE-C19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02603445",
            "title": "Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6461,
                    "therapyName": "BCL201 + Idelalisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02631044",
            "title": "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5980,
                    "therapyName": "JCAR017",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02632396",
            "title": "Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6730,
                    "therapyName": "Ixazomib + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02650999",
            "title": "Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02706392",
            "title": "Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 9192,
                    "therapyName": "Cyclophosphamide + Fludarabine + ROR1 CAR-T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02717624",
            "title": "A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3996,
                    "therapyName": "Acalabrutinib + Bendamustine + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02722668",
            "title": "UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2281,
                    "therapyName": "Cyclophosphamide + Fludarabine + Mycophenolate mofetil",
                    "synonyms": null
                },
                {
                    "id": 917,
                    "therapyName": "Sirolimus",
                    "synonyms": null
                },
                {
                    "id": 1844,
                    "therapyName": "anti-thymocyte globulin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02736617",
            "title": "Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3476,
                    "therapyName": "Ibrutinib + Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02743546",
            "title": "Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4167,
                    "therapyName": "Ibrutinib + JNJ-64052781",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02745769",
            "title": "A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4208,
                    "therapyName": "Merestinib + Ramucirumab",
                    "synonyms": null
                },
                {
                    "id": 4209,
                    "therapyName": "Abemaciclib + Ramucirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02756247",
            "title": "A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3630,
                    "therapyName": "Buparlisib + Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02776813",
            "title": "Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 7267,
                    "therapyName": "ACTR087 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02797470",
            "title": "Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9777,
                    "therapyName": "Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02869633",
            "title": "Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02875002",
            "title": "Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4826,
                    "therapyName": "Belinostat + Volasertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02900716",
            "title": "Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7345,
                    "therapyName": "DTRMWXHS-12 + Everolimus + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 7344,
                    "therapyName": "DTRMWXHS-12",
                    "synonyms": null
                },
                {
                    "id": 7347,
                    "therapyName": "DTRMWXHS-12 + Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02931110",
            "title": "Study of IV CBL0137 in Previously Treated Hematological Subjects",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 3940,
                    "therapyName": "CBL0137",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02950220",
            "title": "Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4917,
                    "therapyName": "Ibrutinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02972840",
            "title": "A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2323,
                    "therapyName": "Bendamustine + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 3996,
                    "therapyName": "Acalabrutinib + Bendamustine + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03010358",
            "title": "Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8065,
                    "therapyName": "Entospletinib + Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03015896",
            "title": "Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5239,
                    "therapyName": "Lenalidomide + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03019640",
            "title": "Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6934,
                    "therapyName": "Carmustine + Cytarabine + Etoposide + Filgrastim + Lenalidomide + Melphalan + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03028103",
            "title": "Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5267,
                    "therapyName": "Fluconazole + Tazemetostat",
                    "synonyms": null
                },
                {
                    "id": 5285,
                    "therapyName": "Omeprazole + Repaglinide + Tazemetostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03037645",
            "title": "Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5281,
                    "therapyName": "SNS-062",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03088878",
            "title": "A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4312,
                    "therapyName": "Cirmtuzumab",
                    "synonyms": null
                },
                {
                    "id": 5480,
                    "therapyName": "Cirmtuzumab + Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03112174",
            "title": "Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 3392,
                    "therapyName": "Ibrutinib + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03147885",
            "title": "Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03153202",
            "title": "Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4917,
                    "therapyName": "Ibrutinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03162536",
            "title": "Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5224,
                    "therapyName": "ARQ 531",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03188965",
            "title": "First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5962,
                    "therapyName": "BAY1895344",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03189836",
            "title": "Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7386,
                    "therapyName": "ACTR707 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03219047",
            "title": "The EXPLORE Trial: Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03232307",
            "title": "Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL)",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1610,
                    "therapyName": "Ibrutinib + Lenalidomide + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03235544",
            "title": "A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3088,
                    "therapyName": "Parsaclisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03267433",
            "title": "Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03277729",
            "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9487,
                    "therapyName": "CD20 CAR T-cells + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03282396",
            "title": "Ibrutinib in Newly Diagnosed Mantle Cell Lymphoma With Low-Risk Disease",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03323151",
            "title": "A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma (PrE0404)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7670,
                    "therapyName": "Ibrutinib + Ixazomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03379493",
            "title": "Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT03424122",
            "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7351,
                    "therapyName": "Ibrutinib + Parsaclisib",
                    "synonyms": null
                },
                {
                    "id": 7350,
                    "therapyName": "Bendamustine + Parsaclisib + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 7349,
                    "therapyName": "Parsaclisib + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03424603",
            "title": "Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7413,
                    "therapyName": "STRO-001",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03440567",
            "title": "Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6780,
                    "therapyName": "Avelumab + Carboplatin + Etoposide + Ifosfamide + Rituximab + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 6781,
                    "therapyName": "Avelumab + Ibrutinib + Rituximab + Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03478514",
            "title": "Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1729,
                    "therapyName": "Ibrutinib + Palbociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03479268",
            "title": "Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7712,
                    "therapyName": "Ibrutinib + MLN4924",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03523975",
            "title": "Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7672,
                    "therapyName": "Lenalidomide + Rituximab + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03537482",
            "title": "APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8825,
                    "therapyName": "APG-2575",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03547115",
            "title": "A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 842,
                    "therapyName": "Voruciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03557619",
            "title": "A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Subjects With Different Hematological Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7978,
                    "therapyName": "Ethinylestradiol + Levonorgestrel + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03571568",
            "title": "A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9353,
                    "therapyName": "BI-1206 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03579927",
            "title": "CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 6213,
                    "therapyName": "iC9/CAR.19/IL15-Transduced CB-NK",
                    "synonyms": null
                },
                {
                    "id": 7797,
                    "therapyName": "Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03585725",
            "title": "A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3167,
                    "therapyName": "Ribavirin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03601819",
            "title": "Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2006,
                    "therapyName": "Pacritinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03617484",
            "title": "Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7671,
                    "therapyName": "Bortezomib + Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03623373",
            "title": "Acalabrutinib With Alternating Cycles of Bendamustine / Rituximab and Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7298,
                    "therapyName": "Acalabrutinib + Bendamustine + Cytarabine + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03674411",
            "title": "Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9613,
                    "therapyName": "Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus",
                    "synonyms": null
                },
                {
                    "id": 9612,
                    "therapyName": "Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03682796",
            "title": "Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8156,
                    "therapyName": "TRPH-222",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03684694",
            "title": "Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7850,
                    "therapyName": "Ibrutinib + Loncastuximab tesirine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03685344",
            "title": "Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7646,
                    "therapyName": "Durvalumab + Loncastuximab tesirine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03696784",
            "title": "Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5992,
                    "therapyName": "Rimiducid",
                    "synonyms": null
                },
                {
                    "id": 7976,
                    "therapyName": "Bendamustine + Fludarabine + iC9/CAR.19/IL15-Transduced CB-NK",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03710772",
            "title": "Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5777,
                    "therapyName": "Ibrutinib + Rituximab + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 7719,
                    "therapyName": "Cyclophosphamide + Dexamethasone + Doxorubicin + Rituximab + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 7720,
                    "therapyName": "Cytarabine + Methotrexate + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03740529",
            "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9507,
                    "therapyName": "Cyclophosphamide + Doxorubicin + LOXO-305 + Prednisone + Rituximab + Vincristine",
                    "synonyms": "LOXO-305 + R-CHOP"
                },
                {
                    "id": 9506,
                    "therapyName": "LOXO-305 + Rituximab + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 9505,
                    "therapyName": "LOXO-305 + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 9504,
                    "therapyName": "LOXO-305",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03779113",
            "title": "An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5279,
                    "therapyName": "HMPL-523",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03786926",
            "title": "Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3669,
                    "therapyName": "HMPL-689",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03834688",
            "title": "Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age (PrE0405)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3637,
                    "therapyName": "Bendamustine + Rituximab + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03863184",
            "title": "Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7994,
                    "therapyName": "Acalabrutinib + Lenalidomide + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03872180",
            "title": "Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3638,
                    "therapyName": "Bendamustine + Obinutuzumab + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03877055",
            "title": "A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6295,
                    "therapyName": "Copanlisib + Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03886831",
            "title": "A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9735,
                    "therapyName": "PRT543",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03920631",
            "title": "Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03939182",
            "title": "Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8303,
                    "therapyName": "Abexinostat + Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03946878",
            "title": "Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7860,
                    "therapyName": "Acalabrutinib + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03997968",
            "title": "A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8486,
                    "therapyName": "CYT01B",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04002297",
            "title": "Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Patients With Untreated Mantle Cell Lymphoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8508,
                    "therapyName": "Rituximab + Zanubrutinib",
                    "synonyms": null
                },
                {
                    "id": 2323,
                    "therapyName": "Bendamustine + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04007029",
            "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5647,
                    "therapyName": "Tocilizumab",
                    "synonyms": null
                },
                {
                    "id": 8530,
                    "therapyName": "Anti-CD19/CD20 CAR T cells + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04043845",
            "title": "ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 8636,
                    "therapyName": "Ibrutinib + LY3214996",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04047797",
            "title": "Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6730,
                    "therapyName": "Ixazomib + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04052854",
            "title": "A Single-Arm, Expanded Access Study of Zanubrutinib (BGB3111) in Patients With B-cell Malignancies",
            "phase": "Expanded access",
            "recruitment": "Available",
            "therapies": [
                {
                    "id": 2544,
                    "therapyName": "Zanubrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04074330",
            "title": "A Study of TAK-981 in Combination With Rituximab in Participants With Relapsed/Refractory (r/r) CD20-positive (CD20+) Non-Hodgkin Lymphoma (NHL)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9146,
                    "therapyName": "Rituximab + TAK-981",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04082936",
            "title": "A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9443,
                    "therapyName": "IGM-2323",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04115631",
            "title": "A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3996,
                    "therapyName": "Acalabrutinib + Bendamustine + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 8868,
                    "therapyName": "Bendamustine + Cytarabine + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 7298,
                    "therapyName": "Acalabrutinib + Bendamustine + Cytarabine + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04160195",
            "title": "T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 8529,
                    "therapyName": "Anti-CD19/CD20 CAR T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04162756",
            "title": "Study of KTE-X19 for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies (ZUMA-18)",
            "phase": "Expanded access",
            "recruitment": "Available",
            "therapies": [
                {
                    "id": 9415,
                    "therapyName": "Cyclophosphamide + Fludarabine + KTE-X19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04189757",
            "title": "Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1605,
                    "therapyName": "Acalabrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04223765",
            "title": "Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9229,
                    "therapyName": "Bendamustine + CAR.k.28 cells + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 9230,
                    "therapyName": "CAR.k.28 cells + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04283097",
            "title": "Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9479,
                    "therapyName": "KPG-818",
                    "synonyms": null
                }
            ]
        }
    ]
}